Taysha Gene Therapies 

Yahoo Finance • 9 days ago

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges

On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities and Exchange Commission (SEC) filing date... Full story

Yahoo Finance • 12 days ago

Taysha Gene Therapies Q4 Earnings Call Highlights

Taysha Gene Therapies logo Key Points Regulatory and trial progress: TSHA-102 received FDA Breakthrough Therapy designation, Taysha has initiated the REVEAL pivotal trial and obtained clearance for the safety-focused ASPIRE study, with F... Full story

Yahoo Finance • 12 days ago

Taysha Gene Therapies GAAP EPS of -$0.34 beats by $0.02, revenue of $9.77M beats by $3.47M

* Taysha Gene Therapies press release [https://seekingalpha.com/pr/20444333-taysha-gene-therapies-reports-full-year-2025-financial-results-and-provides-corporate-update] (TSHA [https://seekingalpha.com/symbol/TSHA]): FY GAAP EPS of -$0.3... Full story

Yahoo Finance • 12 days ago

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to... Full story

Yahoo Finance • 13 days ago

Taysha Gene Therapies FY 2025 Earnings Preview

* Taysha Gene Therapies (TSHA [https://seekingalpha.com/symbol/TSHA]) is scheduled to announce FY earnings results on Thursday, March 19th, before market open. The consensus EPS Estimate is -$0.34 [https://seekingalpha.com/symbol/TSHA/ea... Full story

Yahoo Finance • 25 days ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, March 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monog... Full story

Yahoo Finance • 2 months ago

Taysha Gene Therapies, Inc. (TSHA) Gains Wells Fargo’s Support on Rett Syndrome Program Progress

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Taysha Gene Therapies, Inc. is placed sixth on our list of best biotech stocks under $20. TheFly reported on January 5 that Wells Fargo raised its price targe... Full story

Yahoo Finance • 4 months ago

Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now?

Taysha Gene Therapies Inc. (NASDAQ:TSHA) is a must-buy penny stock to buy now. On November 13, Piper Sandler analyst Biren Amin reaffirmed his Buy rating on Taysha Gene Therapies, assigning a $9 price target. On November 5, Truist Financia... Full story

Yahoo Finance • 5 months ago

Taysha outlines accelerated BLA timeline for TSHA-102 with FDA Breakthrough Therapy designation and full global rights

Earnings Call Insights: Taysha Gene Therapies (TSHA) Q3 2025 MANAGEMENT VIEW * CEO Sean Nolan stated, “The recent regulatory clarity and progress we've achieved, which was enabled by the strength of our REVEAL Part A data set, rigorous... Full story

Yahoo Finance • 5 months ago

Taysha Gene Therapies regains full rights to TSHA-102

designer491/iStock via Getty Images * Taysha Gene Therapies (NASDAQ:TSHA [https://seekingalpha.com/symbol/TSHA]) has announced that it has regained complete rights to its leading program, TSHA-102, which is currently being evaluated for... Full story

Yahoo Finance • 5 months ago

Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome

The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and optionality TSHA-102 has... Full story

Yahoo Finance • 6 months ago

Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory

We came across a bullish thesis on Collegium Pharmaceutical, Inc. on The Catholic Capitalist’s Substack by Logan Shearer. In this article, we will summarize the bulls’ thesis on COLL. Collegium Pharmaceutical, Inc.'s share was trading at $... Full story

Yahoo Finance • 6 months ago

Taysha soars on FDA breakthrough therapy status for lead asset

[FDA headquarters in Washington DC.] JHVEPhoto Taysha Gene Therapies (NASDAQ:TSHA [https://seekingalpha.com/symbol/TSHA]) jumped ~39% on Thursday after the U.S. FDA granted its Breakthrough Therapy designation for the company's lead candi... Full story

Yahoo Finance • 8 months ago

Earnings call transcript: Taysha Gene's Q2 2025 revenue beats forecast

Taysha Gene Therapies Inc. reported its financial results for the second quarter of 2025, revealing a notable revenue beat compared to forecasts. The company posted a revenue of $1.98 million, surpassing the expected $1.82 million, marking... Full story

Yahoo Finance • 8 months ago

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated... Full story

Yahoo Finance • 8 months ago

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12

DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monoge... Full story

Yahoo Finance • 8 months ago

Cumberland Pharmaceuticals Leads The Charge With 2 Other Prominent Penny Stocks

As the U.S. stock market experiences fluctuations with major indices like the Dow Jones and S&P 500 retreating from early-session gains, investors are keenly observing economic indicators and trade developments. Amid these broader market d... Full story

Yahoo Finance • 9 months ago

BofA Securities initiates coverage on Taysha Gene Therapies stock with Buy rating

Investing.com - BofA Securities initiated coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and a price target of $8.00 on Friday. The stock, currently trading at $2.55, has shown strong momentum with a 45% gain over the pa... Full story

Yahoo Finance • 9 months ago

Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory

We came across a bullish thesis on Sarepta Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize the bulls’ thesis on SRPT. Sarepta Therapeutics, Inc.'s share was trading at $17.23 as of... Full story

Yahoo Finance • 10 months ago

Taysha Gene Therapies' SWOT analysis: promising Rett syndrome therapy boosts stock outlook

Taysha Gene Therapies, Inc. (NASDAQ:TSHA), with a market capitalization of $545 million, has emerged as a prominent player in the gene therapy space, focusing on developing treatments for central nervous system (CNS) disorders. The stock h... Full story